Fort Worth, TX – June 19, 2007— Galderma Laboratories, L.P., announced today that the U.S. Food and Drug Administration (FDA) has approved Differin^® (adapalene) Gel, 0.3%, a new, higher concentration formulation of Differin^® (adapalene) 0.1%, a topical retinoid indicated for the treatment of acne. Differin^® Gel, 0.3% provides physicians with a more potent formulation of adapalene that is efficacious enough to treat moderate to moderately-severe acne while still providing a favorable side effect profile. Differin^® Gel, 0.3% will be available by prescription in will be available by prescription the first week in July 2007.

“Differin^® is the #1 prescribed topical acne product by dermatologists¹ and new Differin^® Gel, 0.3% was developed in response to a need for more effective and well-tolerated treatment options to manage moderate to moderately-severe acne,” said Albert Draaijer, President, Galderma USA. “Our clinical studies demonstrate that Differin^® Gel, 0.3% is effective in treating more severe cases of acne, while still offering the favorable tolerability profile which physicians and patients have come to expect from Differin^®. This combination of tolerability and efficacy will further improve outcomes for these patients.

Acne is one of the most common skin problems, affecting as much as 85 percent of the population, and can be challenging to manage. It affects more than 80 percent of young adults and teenagers. The appearance-altering skin disease can cause serious physical and emotional scarring if not treated appropriately.²

Click here to read the rest of the press release.